Pune court rejects injunction against SII over ‘Covishield’ trademark

A civil court in Pune on Saturday rejected an injunction application filed on behalf of pharmaceutical company Cutis Biotech against the Serum Institute of India, seeking the latter to restrain from using the trademark ‘Covishield’ for its Covid-19 vaccine.

Earlier this month, Cutis-Biotech, a pharmaceutical products manufacturer and seller based in Maharashtra, had filed a suit in the civil court seeking to restrain SII from using the trademark ‘Covishield’ or any other similar names for its Covid-19 vaccine, claiming that the pharma company is a prior user of the brand name.

Following this, the Serum Institute of India filed its response in the civil court, saying both the companies operate in different product categories and there is no scope for confusion over the trademark, a company statement said.

Read More: https://www.bhaskarlive.in/pune-court-rejects-injunction-against-sii-over-covishield-trademark/